There is a new COVID variant making headlines in the United States, and this one has an unusual backstory. It is called BA.3.2, but most people tracking it know it by its nickname: "Cicada."
The name fits. Just like the insect that disappears underground for years and then resurfaces all at once, this particular strain of the coronavirus essentially vanished from circulation in early 2022 after a brief appearance — and has now re-emerged with a significantly altered genetic profile. As of April 13, 2026, it has been detected in at least 31 US states and at least 33 countries globally.
How worried should you be? The honest answer is: it warrants attention, but not panic. Here is the full picture.
The Origin Story — Why Cicada Is Different
Most new COVID variants emerge through continuous transmission — the virus copies itself billions of times across millions of people, accumulating small errors (mutations) with each copy. BA.3.2 did not follow that path.
Scientists believe BA.3.2 spent approximately two years inside a single immunocompromised person who could not fully clear the infection. During that prolonged battle between the immune system and the virus, the virus changed substantially. When it eventually re-emerged into wider circulation, it carried a very large number of mutations that the broader population had no experience with.
Normally, a new offshoot of a variant might have a handful of gene changes compared with its parent. BA.3.2 carries roughly 53 changes to its spike protein compared to BA.3, and approximately 70 to 75 mutations compared to the original coronavirus strain from 2019. The spike protein is the part of the virus that docks onto human cells to cause infection — and it is also the target of most COVID vaccines.
That is the core concern.
Where It Is Spreading and How Quickly
BA.3.2 was first identified in South Africa in November 2024. The first US case was detected in June 2025, in a traveler arriving from the Netherlands at San Francisco International Airport. The first clinical case — from a sick patient, not a traveler — was confirmed in January 2026.
Since then, it has been found in wastewater samples from 132 locations across at least 25 states, as well as nasal swabs from patients. As of early April, it accounts for approximately 20% of tested COVID infections in US wastewater, according to WasteWaterSCAN, a Stanford University-led tracking tool.
That is a meaningful jump. When the CDC first released a report on BA.3.2 in mid-March, it accounted for less than 4% of US cases. By early April, that number had risen above 20%.
Still, it is not the dominant strain. XFG remains the most common circulating variant at 53% of wastewater samples, with LF.7 second at 10.3%. Cicada is growing, but it has not taken over.
In parts of Eastern Europe and Australia, Denmark, Germany, and the Netherlands, it is already causing a higher share of cases — up to 30% in some Eastern European locales. The US may be following that trajectory.
Why Children Are Being Affected More Than Usual
One of the more unusual aspects of Cicada is the pattern of who it appears to infect. Scientists say it is showing a higher tendency to affect children — a reversal of the COVID pattern that has held for most of the pandemic, where older adults and people with underlying conditions bore the heaviest burden.
This is not causing more severe disease in kids. The illness in children from BA.3.2 appears to be as mild as other recent COVID variants. But the pattern is scientifically significant because it suggests the virus has changed in ways that affect how it interacts with different immune profiles.
The reason may be immunity-related: adults who have had multiple COVID infections and vaccinations have robust antibody responses against most circulating strains. Cicada's unusual mutation profile may allow it to partially slip past those antibodies in some adults — which could explain why children, who generally have less variant-specific immunity built up, are being picked up more often in samples.
The Vaccine Question — The Most Honest Answer Available Right Now
This is where the reporting gets murky, and it is worth being precise.
Current COVID vaccines — which were formulated based on the JN.1 variant and its descendant LP.8.1 — show reduced effectiveness against BA.3.2 in laboratory studies. BA.3.2 carries between 70 and 75 mutations compared to JN.1-based strains, making it immunologically distinct.
A study published in The Lancet found the current vaccine is less effective against BA.3.2 than against dominant circulating strains, though it still provides some protection.
"The number of mutations from JN.1 viruses makes it less likely that the current vaccines will be highly effective against Cicada, but we need more data to better answer this question," Dr. Robert Hopkins Jr., medical director of the National Foundation for Infectious Diseases, told USA Today. He added: "I have not seen any data which indicates that Cicada is any more severe than other circulating variants."
Critically, the variant is still sensitive to existing COVID antiviral drugs like Paxlovid.
The CDC has added BA.3.2 to its surveillance monitoring list. The WHO has listed it as a "variant under monitoring." Neither organization has elevated it to a "variant of concern."
What Symptoms Look Like
Cicada does not appear to cause distinctly different symptoms from other COVID variants. Common symptoms as per the CDC and clinicians:
- Sore throat (often the first sign)
- Mild to moderate fever
- Body aches and fatigue
- Cough and possible shortness of breath
- Nasal congestion / runny nose
Some early reports have flagged possible gastrointestinal symptoms (nausea, stomach upset) as more common with this strain than with recent Omicron subvariants, though this is not yet confirmed in larger studies.
The problem for diagnosis: these symptoms overlap completely with influenza, RSV, and other springtime respiratory viruses circulating right now. "There is not really a distinct trait between these respiratory illnesses," Dr. Greeta Sood of Johns Hopkins Bayview Medical Center told NBC News. Testing is the only way to confirm.
What Experts Recommend Right Now
The practical guidance from infectious disease specialists is not dramatically different from standard COVID precautions:
- If you have a fever accompanying spring sniffles, take a COVID test — don't assume it's allergies
- If you test positive, seek antiviral treatment promptly, especially if you are elderly, immunocompromised, or have underlying conditions
- Stay up to date on your vaccinations. Even reduced effectiveness is not zero protection — vaccines are expected to continue providing meaningful defence against severe illness
- Wear masks in crowded indoor spaces if you are in a high-risk group
- Stay home when symptomatic
There is no indication the US is heading toward a major Cicada-driven wave. Overall COVID activity remains low nationally. But the variant's rate of growth — from 4% to 20% of wastewater samples in under a month — means it is gaining ground and should be tracked closely through summer.
Sources
- TODAY / NBC News (April 13, 2026) — most comprehensive US spread overview, 31-state count, expert quote
